Collegium Pharmaceutical (COLL) News Today $30.15 -0.41 (-1.34%) As of 03/25/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday.March 25 at 8:12 AM | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Given "Buy" Rating at HC WainwrightMarch 25 at 1:43 AM | americanbankingnews.comForecasting The Future: 4 Analyst Projections For Collegium PharmaceuticalMarch 24 at 12:17 PM | benzinga.comEmerald Advisers LLC Has $23.26 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Emerald Advisers LLC lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 811,680 shares of the specialty pharmaceutical companyMarch 24 at 7:08 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 367,406 sharesMarch 23 at 3:02 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Intech Investment Management LLCIntech Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 593.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,132 shares of the specialty pharmaceuMarch 22, 2025 | marketbeat.comAmundi Has $446,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Amundi raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 188.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,568 shares of the specialty pharmaceutical company's stock afMarch 21, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper Sells 977 SharesCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 977 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. This represents a 0.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.March 19, 2025 | marketbeat.comInsider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 2,255 Shares of StockCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares of the company's stock, valued at approximately $3,732,630. This represents a 1.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.March 19, 2025 | marketbeat.comTejara Capital Ltd Makes New $825,000 Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Tejara Capital Ltd bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 28,781 shares of the specialty pharmaceutical company's stock, valMarch 19, 2025 | marketbeat.comInsider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells 977 Shares of StockMarch 19, 2025 | insidertrades.comRoyce & Associates LP Acquires 33,674 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Royce & Associates LP increased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 11.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 339,529 shares of the specialty pharmaceutical coMarch 19, 2025 | marketbeat.comIBD Rating Upgrades: Teva Pharmaceutical ADR Flashes Improved Relative Price StrengthMarch 18, 2025 | msn.comCollegium announces updates to its board of directors, executive teamMarch 18, 2025 | markets.businessinsider.comCollegium Pharmaceutical, Inc. Announces New Chairman and Executive Leadership Appointments Amid Board ChangesMarch 17, 2025 | quiverquant.comCollegium Announces Updates to its Board of Directors and Executive Leadership TeamMarch 17, 2025 | globenewswire.comVestcor Inc Acquires 13,990 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Vestcor Inc boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 540.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,578 shares of the specialty pharmaceutical company's stMarch 17, 2025 | marketbeat.comBank of New York Mellon Corp Has $7.24 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Bank of New York Mellon Corp cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 252,687 shares of the speciaMarch 16, 2025 | marketbeat.comColleen Tupper Sells 10,445 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 10,445 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. The trade was a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.March 14, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper Sells 10,445 SharesMarch 14, 2025 | insidertrades.comVictory Capital Management Inc. Reduces Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Victory Capital Management Inc. trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 21.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 559,536 shares of the specialty pharmaceMarch 13, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $58,470.00 in StockCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares of the company's stock, valued at $5,315,850. The trade was a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 11, 2025 | marketbeat.comColleen Tupper Sells 1,949 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockMarch 11, 2025 | insidertrades.comCollegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health CareMarch 10, 2025 | globenewswire.comCollegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025March 9, 2025 | seekingalpha.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann Sells 26,067 SharesCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 26,067 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now owns 108,137 shares of the company's stock, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.March 7, 2025 | marketbeat.comShirley R. Kuhlmann Sells 40,000 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 7, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Trading Up 4.6% - Time to Buy?Collegium Pharmaceutical (NASDAQ:COLL) Trading 4.6% Higher - What's Next?March 7, 2025 | marketbeat.comShirley R. Kuhlmann Sells 26,067 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) StockMarch 7, 2025 | insidertrades.comPiper Sandler Reaffirms Their Hold Rating on Collegium Pharmaceutical (COLL)March 7, 2025 | markets.businessinsider.comCollegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong FactorsMarch 6, 2025 | finance.yahoo.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week Low - What's Next?Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 12-Month Low - What's Next?March 5, 2025 | marketbeat.comCollegium to Participate in Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Artelo Biosciences (ARTL), Syndax Pharmaceuticals (SNDX)March 4, 2025 | markets.businessinsider.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from BrokeragesCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have issued a buy ratiMarch 4, 2025 | marketbeat.comCollegium Pharmaceutical: Checking The BoxesMarch 3, 2025 | seekingalpha.comChesterfield pharma company Indivior announces CEO changeMarch 1, 2025 | bizjournals.comCollegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up After Strong EarningsCollegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up After Earnings BeatMarch 1, 2025 | marketbeat.comIs Collegium Pharmaceutical, Inc. (COLL) the Best Small Cap Pharma Stocks to Buy Now?March 1, 2025 | insidermonkey.comCollegium Pharmaceutical (NASDAQ:COLL) Announces Earnings Results, Beats Expectations By $0.09 EPSCollegium Pharmaceutical (NASDAQ:COLL - Get Free Report) issued its earnings results on Thursday. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%.February 28, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | insidermonkey.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comCollegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comCollegium Pharmaceutical backs FY25 revenue view $735M-$750M, consensus $740.44MFebruary 27, 2025 | markets.businessinsider.comCollegium Pharmaceutical reports Q4 adjusted EPS $1.77, consensus $1.54February 27, 2025 | markets.businessinsider.comCollegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%February 27, 2025 | msn.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low - Should You Sell?Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month Low - What's Next?February 27, 2025 | marketbeat.comIndivior names Joseph Ciaffoni as CEOFebruary 27, 2025 | msn.comIndivior names Joseph Ciaffoni as CEOFebruary 27, 2025 | msn.com Remove Ads Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Media Mentions By Week COLL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼0.900.70▲Average Medical News Sentiment COLL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼145▲COLL Articles Average Week Remove Ads Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RARE News Today SWTX News Today AKRO News Today ALVO News Today RYTM News Today MRUS News Today CRNX News Today IMVT News Today VKTX News Today PTGX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COLL) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
